| ABSTRACT Objective:To study the efficacy and safety of tolvaptan on treatment of hyponatremia caused by lung cancer.Methods: 36 patients with hyponatremia caused by syndrome of inappropriate antidiuretic hormone secretion(SIADH) in lung cancer were randomly divided into therapy group （18 cases，conventional treatment + tolvaptan） and control group （18 cases，conventional treatment + placebo）. After seven days treatment，the clinical effect and safety were compared between two groups. Results: After treatment, the blood sodium level and plasma osmotic pressure of the two groups were both higher than before(P<0.05), 24 hours urine volume were both increased than before(P<0.01); and after treatment, the blood sodium level and plasma osmotic pressure of the therapy group were significantly higher than the control group(P<0.01), 24h urine volume was evidently higher than that of the control group(P<0.01).The changes of the weight, blood pressure and heart rate were in normal range comparing the groups before treatment with the groups after treatment, meanwhile the difference between two groups represented no statistical significance(P＞0.05). With the increase of tolvaptan dose, the blood sodium concentration increased gradually ;There were no severe complication and adverse reaction,and only 3 cases of dry mouth were found in therapy group. Conclusion:Tolvaptan had distinct therapeutic effect for patients with hyponatremia caused by lung cancer,and it could improve their qualities of life with good safety reliability. |
